Data Announced on the Estimated Economic Impact of Treating Myelosuppression for ES-SCLC

Article

Two posters on the efficacy of trilaciclib for treating myelosuppression were presented at the Virtual International Society for Pharmacoeconomics and Outcomes Research 2021.

A pair of posters were presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) focusing on the estimated economic impact of treating myelosuppression for patients with extensive-stage small cell lung cancer (ES-SCLC), according to the company responsible for the data, G1 Therapeutics, Inc.1

The first poster focused on the cost-benefit analysis of preventing chemotherapy-induced myelosuppression with trilaciclib (Cosela) for this cohort of patients. The second poster analyzed the trends in prevalence, treatment patterns, myelosuppression, and health care burden for patients with SCLC.

“Chemotherapy remains a cornerstone of treatment for SCLC, and chemotherapy-induced myelosuppression is a frequent complication that may manifest as neutropenia, anemia, and/or thrombocytopenia,” Marc Chioda, PharmD, Vice President of Medical Affairs at G1 and co-author of both posters, said in a press release.

In the first scientific poster, the investigative team concluded that a cost-benefit model estimating the economic value of trilaciclib incorporated prior to chemotherapy for patients with ES-SCLC shows that trilaciclib could be economically favorable to address the incidence of myelosuppression.2

The cost-benefit model estimated a potential cost savings per patient of $15,006 based on a projected reduction of myelosuppressive adverse effects (AEs) and the costs associated with them. Using trilaciclib prior to chemotherapy was associated with fewer myelosuppressive AEs, with 0.6 events observed in patients with trilaciclib compared with 2.7 events for patients with trilaciclib.

The second poster presented findings on the impact of treatment-induced myelosuppression for Medicare patients with SCLC. According to the Surveillance, Epidemiology, and End Results (SEER)–Medicare analysis, the reported data suggest that myelosuppression poses a substantial burden on the health care system.3

Some of the integral findings included nearly 75% of patients treated with chemotherapy experienced anemia during the study timeframe. More, AEs reported among the patient population treated with chemotherapy included neutropenia (45.2%) and thrombocytopenia (27.0%). Pancytopenia was observed in 24.4% of all patients included in the research.

“These analyses add to the data that help clarify the potential positive financial impact of Cosela usage and the projected real-world economic value of Cosela,” explained Chioda. “Together, these data suggest that use of Cosela should be a favorable economic strategy in the first line of therapy compared with standard care.”

Trilaciclib was previously approved by the FDA on February 12, 2021, for decreasing the incidence of chemotherapy-induced myelosuppression prior to a platinum/etoposide-containing regimen or topotecan-containing regimen to treat ES-SCLC.4

The most common AEs associated with trilaciclib, defined as occurring in greater than 10% of patients, include fatigue, hypocalcemia, hypokalemia, hypophosphatemia, aspartate aminotransferase increased, headache, and pneumonia.

Reference:

1. G1 therapeutics presents two posters at ISPOR describing the estimated economic impact of treating myelosuppression among patients with extensive-stage small cell lung cancer. News release. G1 Therapeutics. Published May 17, 2021. Accessed May 26, 2021. http://investor.g1therapeutics.com/news-releases/news-release-details/g1-therapeutics-presents-two-posters-ispor-describing-estimated

2. Deniz B, Onyekwere U, Moran D, et al. Cost-Benefit Analysis of Trilaciclib for the Prevention of Chemotherapy-Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer. Presented at: International Society for Pharmacoeconomics and Outcomes Research; May 17-20, 2021. Virtual. Accessed May 27, 2021. https://bit.ly/2TeYQpC

3. Epstein R, Nelms J, Moran D, et al. Trends in Prevalence, Treatment Patterns, Myelosuppression, and Burden on the Health Care System Among Patients with Small Cell Lung Cancer: A SEER-Medicare Analysis. Presented at: International Society for Pharmacoeconomics and Outcomes Research; May 17-20, 2021. Virtual. Accessed May 27, 2021. https://bit.ly/2SwTPsb

4. FDA approves drug to reduce bone marrow suppression caused by chemotherapy. News release. February 12, 2021. Accessed February 12, 2021. https://bit.ly/34m1lZN

Related Videos
The use of novel agents like tarlatamab may be “interesting” among patients with small cell lung cancer in the relapsed setting, says Gregory Peter Kalemkerian, MD.
Prophylactic cranial irradiation may not be worthwhile for treating patients with extensive-stage small cell lung cancer based on conflicting data, according to Gregory Peter Kalemkerian, MD.
FDA-approved immunotherapy options such as atezolizumab and durvalumab have produced substantial benefits in certain groups of patients with extensive-stage small cell lung cancer, says Gregory Peter Kalemkerian, MD.
small cell lung cancer
Related Content
Treatment with durvalumab raises no new safety signals among patients with limited-stage small cell lung cancer in the phase 3 ADRIATIC trial.

Durvalumab Significantly Improves Survival in Limited-Stage SCLC

April 5th 2024
Article

Treatment with durvalumab raises no new safety signals among patients with limited-stage small cell lung cancer in the phase 3 ADRIATIC trial.

Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.

Updated ASCO Guidelines for Optimal Small Cell Lung Cancer Management

March 25th 2024
Podcast

Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.

The FDA sets a Prescription Drug User Fee Act date of June 12, 2024, for tarlatamab as a therapy for patients with advanced small cell lung cancer.

Tarlatamab Earns FDA Priority Review in Advanced Small Cell Lung Cancer

December 14th 2023
Article

The FDA sets a Prescription Drug User Fee Act date of June 12, 2024, for tarlatamab as a therapy for patients with advanced small cell lung cancer.

In the final part of the small cell lung cancer podcast series, CancerNetwork® and Wade Iams, MD, discuss the future of treating patients with this disease.

Oncology Peer Review On-The-Go: Future Directions in Small Cell Lung Cancer Treatment

December 22nd 2021
Podcast

In the final part of the small cell lung cancer podcast series, CancerNetwork® and Wade Iams, MD, discuss the future of treating patients with this disease.

Findings from the phase 3 SKYSCRAPER-02 trial support outcomes following atezolizumab plus chemotherapy for patients with extensive-stage small cell lung cancer.

Tiragolumab Combo Does Not Improve Outcomes in Untreated ES-SCLC

November 21st 2023
Article

Findings from the phase 3 SKYSCRAPER-02 trial support outcomes following atezolizumab plus chemotherapy for patients with extensive-stage small cell lung cancer.

Patients with extensive-stage small cell lung cancer who receive trilaciclib appear to experience lower rates of hematologic adverse effects than those who are not treated with the agent.

Trilaciclib May Reduce Hospitalization and Improve Survival in ES-SCLC

November 3rd 2023
Article

Patients with extensive-stage small cell lung cancer who receive trilaciclib appear to experience lower rates of hematologic adverse effects than those who are not treated with the agent.